Skip to main content
Top
Published in: Pathology & Oncology Research 3/2019

01-07-2019 | Original Article

Assessment of Gastritis and Gastric Cancer Risk in the Chilean Population Using the OLGA System

Authors: Enrique Bellolio, Ismael Riquelme, Angela L. Riffo-Campos, Carlos Rueda, Catterina Ferreccio, Miguel Villaseca, Priscilla Brebi, Sergio Muñoz, Juan Carlos Araya

Published in: Pathology & Oncology Research | Issue 3/2019

Login to get access

Abstract

Gastric cancer (GC) is the first cancer-related cause of death in Chile; however, no plan for GC early detection has been implemented in this country. The OLGA system characterizes gastritis from stages 0 to IV according to the risk of developing GC based on H. pylori infection, atrophy, metaplasia and GC. In this study, the performance of the OLGA system was evaluated in 485 Chilean patients receiving routine endoscopy to improve the detection of early GC or preneoplastic lesions. The results showed that OLGA scores, atrophy, metaplasia and GC increased significantly with age (p < 0.001). Conversely, H. pylori infection was higher in younger groups (p < 0.05). All gastric lesions were more frequent in men than women. The majority of patients with atrophy also had metaplasia (99%, p < 0.0001). Patients with H. pylori infection had more gastric atrophy and metaplasia than those without infection (p < 0.05). Of the 485 patients, 21 (4.3%) had GC, being 2.3 times more frequent among men than women and about 2/3 (14) were in OLGA stage ≥2. In addition, 19 (90%) GC patients had atrophy and 18 (85%) had metaplasia (p < 0.001). In conclusion, the OLGA system facilitated the evaluation of GC precursor lesions particularly in patients with an OLGA score > 2 between 45 and 56 years old, because this group showed atrophy and intestinal metaplasia more frequently. Therefore, biennial endoscopic surveillance of patients with an OLGA >2 can be an important health policy in Chile for diagnosing GC in its early stages and reducing mortality over the next two decades.
Literature
8.
go back to reference IARC (2014) Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer (IARC Working Group Reports Volume 8) IARC (2014) Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer (IARC Working Group Reports Volume 8)
12.
go back to reference Correa P, Piazuelo MB (2011) Helicobacter pylori infection and gastric adenocarcinoma. US Gastroenterol Hepatol Rev 7:59–64PubMedPubMedCentral Correa P, Piazuelo MB (2011) Helicobacter pylori infection and gastric adenocarcinoma. US Gastroenterol Hepatol Rev 7:59–64PubMedPubMedCentral
13.
go back to reference Correa P (1992) Human gastric carcinogenesis: a multistep and multifactorial process--first American Cancer Society award lecture on Cancer epidemiology and prevention. Cancer Res 52:6735–6740PubMed Correa P (1992) Human gastric carcinogenesis: a multistep and multifactorial process--first American Cancer Society award lecture on Cancer epidemiology and prevention. Cancer Res 52:6735–6740PubMed
15.
go back to reference Pasechnikov VD, Chukov SZ, Kotelevets SM, Mostovov AN, Mernova VP, Polyakova MB (2005) Invasive and non-invasive diagnosis of helicobacter pylori-associated atrophic gastritis: a comparative study. Scand J Gastroenterol 40:297–301CrossRefPubMed Pasechnikov VD, Chukov SZ, Kotelevets SM, Mostovov AN, Mernova VP, Polyakova MB (2005) Invasive and non-invasive diagnosis of helicobacter pylori-associated atrophic gastritis: a comparative study. Scand J Gastroenterol 40:297–301CrossRefPubMed
20.
go back to reference Dixon MF, Genta RM, Yardley JH, Correa P (1996) Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol 20:1161–1181CrossRef Dixon MF, Genta RM, Yardley JH, Correa P (1996) Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol 20:1161–1181CrossRef
22.
go back to reference Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H, Yoshikawa A, Yanaoka K, Arii K, Tamai H, Shimizu Y, Takeshita T, Mohara O, Ichinose M (2004) Progression of chronic atrophic gastritis associated withHelicobacter pylori infection increases risk of gastric cancer. Int J Cancer 109:138–143. https://doi.org/10.1002/ijc.11680 CrossRefPubMed Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H, Yoshikawa A, Yanaoka K, Arii K, Tamai H, Shimizu Y, Takeshita T, Mohara O, Ichinose M (2004) Progression of chronic atrophic gastritis associated withHelicobacter pylori infection increases risk of gastric cancer. Int J Cancer 109:138–143. https://​doi.​org/​10.​1002/​ijc.​11680 CrossRefPubMed
29.
go back to reference Namekata T, Miki K, Kimmey M et al (2000) Chronic atrophic gastritis and helicobacter pylori infection among Japanese Americans in Seattle. Am J Epidemiol 151(8):820–830CrossRefPubMed Namekata T, Miki K, Kimmey M et al (2000) Chronic atrophic gastritis and helicobacter pylori infection among Japanese Americans in Seattle. Am J Epidemiol 151(8):820–830CrossRefPubMed
Metadata
Title
Assessment of Gastritis and Gastric Cancer Risk in the Chilean Population Using the OLGA System
Authors
Enrique Bellolio
Ismael Riquelme
Angela L. Riffo-Campos
Carlos Rueda
Catterina Ferreccio
Miguel Villaseca
Priscilla Brebi
Sergio Muñoz
Juan Carlos Araya
Publication date
01-07-2019
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2019
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-018-0532-3

Other articles of this Issue 3/2019

Pathology & Oncology Research 3/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine